EARLY PSA RESPONSE IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH MCRPC TREATED WITH NEXT-GENERATION ANDROGEN PATHWAY INHIBITORS

被引:1
|
作者
Fuerea, A. C. [1 ]
Baciarello, G. [1 ]
Massard, C. [2 ]
Sauvin, L. Albiges [3 ]
Gizzi, M. [1 ]
Terrisse, S. A. [4 ]
Di Palma, M. [1 ]
Escudier, B. [5 ]
Fizazi, K. [6 ]
Loriot, Y. [5 ]
机构
[1] Inst Gustave Roussy, Villejuif, France
[2] Inst Gustave Roussy, SITEP, Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Inst Canc Res, Dept Med Oncol, Villejuif, France
[5] Inst Cancerol Gustave Roussy, Villejuif, France
[6] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
关键词
D O I
10.1093/annonc/mdu336.44
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
796P
引用
收藏
页数:1
相关论文
共 50 条
  • [11] PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation
    McDonald, Andrew M.
    Jacob, Rojymon
    Yang, Eddy S.
    Dobelbower, Michael C.
    Vanlandingham, Sean
    Fiveash, John B.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 687 - 693
  • [12] Reply to Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy
    de Crevoisier, R.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 904 - U241
  • [13] Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
    Wefel, Jeffrey S.
    Ryan, Charles J.
    Van, Julie
    Jackson, James C.
    Morgans, Alicia K.
    CNS DRUGS, 2022, 36 (05) : 419 - 449
  • [14] Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
    Jeffrey S. Wefel
    Charles J. Ryan
    Julie Van
    James C. Jackson
    Alicia K. Morgans
    CNS Drugs, 2022, 36 : 419 - 449
  • [15] Prognostic performance of the next-generation sequencing- based multigene assay in early breast cancer patients treated according to the 21-gene assay results
    Cheun, J. -H
    Kang, E.
    Lee, J.
    Lee, H.
    Park, J. -Y
    Lee, H. J.
    Kang, B.
    Park, W. K.
    Son, J.
    Kim, B.
    Chung, W.
    Han, W.
    Lee, H. -B
    Lee, S. B.
    Ryu, J. M.
    BREAST, 2025, 80
  • [16] Tumor response is an independent prognostic factor in patients (pts) treated for metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Lin, X.
    Kalanovic, D.
    McKay, R.
    Perkins, J.
    Simantov, R.
    Choueiri, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S642 - S642
  • [17] PSA Response to Neoadjuvant Androgen Deprivation Is an Independent Prognostic Marker and May Identify Patients Who Benefit From Pelvic Lymph Node Irradiation
    McDonald, A.
    Jacob, R.
    Yang, E. S.
    Dobelbower, M. C.
    Fiveash, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S389 - S389
  • [18] Next-generation sequencing reveals genomic determinants of long-term response to mTOR inhibitors in patients with advanced RCC
    Voss, M. H.
    Hakimi, A. A.
    Brannon, A. R.
    Scott, S.
    Takeda, S.
    Liu, H.
    Chen, Y.
    Motzer, R. J.
    Berger, M. F.
    Hsieh, J. J.
    BJU INTERNATIONAL, 2012, 110 : 11 - 11
  • [19] The Role of Next-Generation Sequencing in Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with VRD Regimen
    Cheng, Lili
    Zhang, Fujing
    Li, Ziping
    Zhuang, Junling
    Cai, Hao
    Li, Hui
    BLOOD, 2024, 144 : 6856 - 6856
  • [20] Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy.
    Fizazi, K
    Slimane, K
    Eschwege, F
    Wibault, P
    De Crevoisier, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 427S - 427S